Plain-English translation of NCT03214562 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether , a newer medication, works better when combined with standard chemotherapy drugs for treating acute myeloid leukemia (AML)—a serious blood cancer. The first phase of the trial will find the safest dose of this medication when used with chemotherapy, and the second phase will test how well this combination actually works. If you have newly diagnosed AML or AML that has come back or didn't respond to previous treatment, this trial may be an option for you.
Acute myeloid leukemia is very serious, and while standard chemotherapy has been used for years, researchers want to see if adding this newer medication can improve outcomes and help more patients go into remission. This trial addresses the need to find better treatment options, especially for patients whose cancer has returned or resisted previous therapy.
You likely qualify if…
You likely don't qualify if…
You would receive treatment in phases over several months to a year. First, you would take the medication by mouth for 14 days while receiving chemotherapy drugs through an IV twice a week for 5 days, with growth factor support. This induction phase repeats every 28 days for up to 2 cycles. Then you would move to consolidation therapy for up to 6 cycles, where the medication dose decreases slightly but the chemotherapy schedule is shorter. Finally, if your cancer responds well, you would receive the medication alone by mouth for up to one year as maintenance therapy. You would have regular blood tests and doctor visits throughout to monitor your response and any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States